Organs

Bladder Scanner Market: COVID-19 Business Continuity Plan | Evolving Opportunities with Becton, Dickinson and Co. and Caresono Technology Co. Ltd. | Technavio

Retrieved on: 
Wednesday, September 9, 2020
Medical devices, Health, Organs, Pelvis, Urinary bladder, Urinary system, BD, Branches of biology, Industries

View the full release here: https://www.businesswire.com/news/home/20200909005573/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200909005573/en/
    Technavio has announced its latest market research report titled Global Bladder Scanner Market 2020-2024 (Graphic: Business Wire)
    Read the 120-page report with TOC on "Bladder Scanner Market Analysis Report by End-user (Hospitals, Clinics, and Others), Type (3D bladder scanner and 2D bladder scanner), Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts, 2020-2024".
  • Major Five Bladder Scanner Companies:
    Becton, Dickinson and Co. operates its business through segments such as BD Medical, BD Life Sciences, and BD Interventional.
  • The company offers BBS Revolution bladder scanner, BARDSCAN IIs Real Time Ultrasound Bladder Scanner, and others.
  • The company offers products such as PadScan HD2 Bladder Scanner, PadScan HD5 Bladder Scanner, and PadScan HD3 Bladder Scanner.

Chennai Boy Undergoes First of Its Kind Living Donor Liver Transplant in India for Rare Metabolic Disease

Retrieved on: 
Saturday, September 5, 2020
Health, Hospitals, Surgery, Genetics, Other Health, General Health, Medical specialties, Clinical medicine, Hepatology, Rare diseases, Lipid storage disorders, Liver, Organs, Chronic liver disease, Lysosomal acid lipase deficiency, Organ transplantation, Acid lipase disease, Tyrosinemia type I

A 16 years old boy from Chennai who was suffering from decompensated chronic liver disease due to Cholesteryl ester storage disease, has undergone successful liver transplant at Gleneagles Global Health City.

Key Points: 
  • A 16 years old boy from Chennai who was suffering from decompensated chronic liver disease due to Cholesteryl ester storage disease, has undergone successful liver transplant at Gleneagles Global Health City.
  • This is one among the rare genetic liver diseases which affects the liver at childhood and further leads to liver failure as the child grows older.
  • The boy was on his feet from 3rd day post liver transplant and resumed his normal diet from the 5th day onwards.
  • It was the rarest case in India to undergo successful liver transplant for this type of metabolic disorder.

Gregory Tinnen's new book "Sleep Nosis" helps readers tap into the unconscious, revealing a world of lucid flying dreams, incredible visions, premonitions and much more

Retrieved on: 
Friday, September 4, 2020
Anatomy, Animal anatomy, Brain, Organs, Sleep, Magnetic resonance imaging, Branches of biology, Mind

Any age, any sex, any religion, any culture can benefit from these techniques.

Key Points: 
  • Any age, any sex, any religion, any culture can benefit from these techniques.
  • When the brain is studied with magnetic resonance imaging, two things stand out as lighting up the entire brain.
  • "SleepNosis" by Gregory Tinnen is a safe way to light up the entire brain, resulting in a lucid awake sleep state that is controllable.
  • Published by Page Publishing, this engrossing book is a must-read for anyone fascinated by the unlimited potential of their own mind.

New Coalition for Liver Health Announces Free Liver Health Diet Kits for Truckers

Retrieved on: 
Wednesday, September 2, 2020
Food and drink, Nutrition, Liver, Organs, Dietary Reference Intake, Health, Truck driver, Articles

For National Truck Driver Appreciation Week, HTTA and Amsety will provide 60 dedicated free Liver Health Diet Kits for fleets and drivers.

Key Points: 
  • For National Truck Driver Appreciation Week, HTTA and Amsety will provide 60 dedicated free Liver Health Diet Kits for fleets and drivers.
  • Each kit includes free Amsety Liver Health Bars as well as educational material on liver health.
  • HTAA Health Coaches will use Amsety's Truckers Liver Health Score as a tool to assess drivers lifestyle habits and the effects on their liver health.
  • Developed by leading liver health experts, Amsety Bars are a breakthrough in the U.S. market being the first nutrition bars to support liver health and meet special dietary requirements for liver health.

Trilogy Laboratories Launches Screen Saver Serum to Shield Skin from Blue Light Damage

Retrieved on: 
Wednesday, September 2, 2020
Electromagnetic radiation, Electrodynamics, Radiation, Ultraviolet radiation, Organs, Sun tanning, Ultraviolet, Skin care, Skin

Trilogy Laboratories' new Screen Saver serum protects skin from the harmful effects of blue light and other environmental factors.

Key Points: 
  • Trilogy Laboratories' new Screen Saver serum protects skin from the harmful effects of blue light and other environmental factors.
  • "Most skin care products focus primarily on the sun's UVA and UVB rays, but Screen Saver protects the skin from blue light," explains Kristen Flaharty, PharmD, Founder of Trilogy Laboratories.
  • "Blue light can penetrate deep into the skin and cause oxidative stress contributing to premature skin aging, such as skin darkening and age spots.
  • Our new Screen Saver serum goes the extra mile to minimize the appearance of aging and reduce skin damage caused by exposure to blue light."

Liver Disease Diagnostics Industry to Reach $40.7 Billion by 2026 - Breakdown by Diagnosis Technique, End User and Region

Retrieved on: 
Monday, August 24, 2020
Medical specialties, Anatomy, Clinical medicine, RTT, Hepatology, Hepatitis, Liver, Organs, Non-alcoholic fatty liver disease, Alcoholic liver disease, Cirrhosis, Fatty liver disease

DUBLIN, Aug. 24, 2020 /PRNewswire/ -- The "Global Liver Disease Diagnostics Market By End User, By Diagnosis Technique, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 24, 2020 /PRNewswire/ -- The "Global Liver Disease Diagnostics Market By End User, By Diagnosis Technique, By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Liver Disease Diagnostics Market is expected to reach $40.7 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period.
  • With better living conditions, the prevalence of the chronic liver disease, including non-alcoholic fatty liver disease and alcohol-related liver disease, is expected to escalate, potentially leading to more cases of end-stage liver disease (liver failure, cirrhosis, and liver cancer).
  • Furthermore, the increasing geriatric population has contributed to significant growth in the global demand for the treatment of liver disease.

CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020

Retrieved on: 
Thursday, August 20, 2020
Medical specialties, Liver, Hepatology, Digestive diseases, RTT, Organs, Cirrhosis, Autoimmune diseases, Primary biliary cholangitis, Non-alcoholic fatty liver disease

NEWARK, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that two seladelpar presentations will be delivered during the Digital International Liver Congress 2020 of the European Association for the Study of Liver (EASL) which will be held online August 27th 29th.

Key Points: 
  • NEWARK, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that two seladelpar presentations will be delivered during the Digital International Liver Congress 2020 of the European Association for the Study of Liver (EASL) which will be held online August 27th 29th.
  • Sujal Shah, CEO and President of CymaBay Therapeutics, commented, We are excited to share the final results from an open-label Phase 2 study of seladelpar in PBC.
  • There is an accompanying inflammation and destruction of the intrahepatic bile ducts, which can progress to fibrosis, cirrhosis and liver failure.
  • CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need.

GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China

Retrieved on: 
Monday, August 17, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medicine, Health, Liver, Organs, Fibrosis, Branches of biology

GNI Group Ltd. (GNI Group; TSE Mothers 2160), a commercial-stage biopharmaceutical company, today announced positive results from the initial analysis of Phase II clinical trial of the F351 drug candidate for liver fibrosis.

Key Points: 
  • GNI Group Ltd. (GNI Group; TSE Mothers 2160), a commercial-stage biopharmaceutical company, today announced positive results from the initial analysis of Phase II clinical trial of the F351 drug candidate for liver fibrosis.
  • The study met its primary endpoint of a statistically significant improvement in the liver fibrosis score over the 52-week treatment versus placebo (p=0.025).
  • I am thrilled by the initial results of the Phase II study, which underscores the potential for F351 to benefit millions of liver fibrosis patients worldwide, said Dr. Ying Luo, President of GNI Group.
  • GNI Group Ltd. does not expect the aforementioned matter will impact financial results for the year ending December 31, 2020.

Excess Weight Among Pregnant Women May Interfere With Child's Developing Brain

Retrieved on: 
Tuesday, August 11, 2020
Branches of biology, Anatomy, Neuroscience, Cognitive neuroscience, Neuroimaging, Animal anatomy, Brain, Organs, Electroencephalography, Connectome, Functional magnetic resonance imaging

Using millions of computations, the study authors divided the groups into 16 meaningful subgroups based on over 19,000 possible connections between the groups of neurons.

Key Points: 
  • Using millions of computations, the study authors divided the groups into 16 meaningful subgroups based on over 19,000 possible connections between the groups of neurons.
  • They found only two areas of the brain where their connections to each other were statistically strongly linked to the mother's BMI.
  • Previous studies showing an association between obesity and brain development had mostly looked at cognitive function in children after birth.
  • The research team used MRI imaging to measure fetal brain activity and map patterns of communication between large numbers of brain cells clustered together in different regions of the brain.

Global Chronic Liver Disease Therapeutics Market to Surpass US$ 24.9 Billion by 2027, Says Coherent Market Insights

Retrieved on: 
Thursday, July 30, 2020
Research, FDA, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Medical specialties, RTT, Medicine, Hepatology, Clinical medicine, Liver, Organs, Chronic liver disease, Chronic condition, Cancer, Hepatocellular carcinoma, Non-alcoholic fatty liver disease

Approval and launch of novel therapies for treatment of liver diseases is expected to drive growth of the global chronic liver disease therapeutics market.

Key Points: 
  • Approval and launch of novel therapies for treatment of liver diseases is expected to drive growth of the global chronic liver disease therapeutics market.
  • Furthermore, the increasing prevalence of liver cancer is expected to propel growth of the global chronic liver diseases therapeutics market during the forecast period.
  • The global chronic liver diseases therapeutics market is expected to witness significant growth owing to increasing research for identifying the causes of liver cancer.
  • Key players in the North America chronic liver diseases therapeutics market are focused on launching new products in this market.